Interestingly, in this study, both clusters presented high levels of CD39, providing evidence that CD39 inhibition may represent a therapeutic target for both Treg and CD8+ T cells in iCCA patients [35]. This evidence concerns the gene ENTPD1 and infantile convulsions and choreoathetosis.